Participation of the elderly population in clinical trials: Barriers and solutions

Cancer Control

Volumn 21, Issue 3, 2014, Pages 209-214

  Denson, Aaron C ^a   Mahipal, Amit ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGEISM; ARTICLE; CANCER RESEARCH; COMORBIDITY; CULTURAL FACTOR; DRUG EFFICACY; DRUG METABOLISM; GERIATRIC PATIENT; HUMAN; INTERPERSONAL COMMUNICATION; PATIENT AUTONOMY; PATIENT PARTICIPATION; PATIENT SELECTION; PHYSICIAN ATTITUDE; QUALITY OF LIFE; RESEARCH SUBJECT; AGE; CLINICAL TRIAL (TOPIC); FEMALE; MALE; PROCEDURES; TREATMENT OUTCOME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; PATIENT PARTICIPATION; TREATMENT OUTCOME;

EID: 84903163207     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481402100305     Document Type: Article

References (37)

1. American Cancer Society. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society; 2014.
2. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117-128.
3. Knickman JR, Snell EK. The 2030 problem: caring for aging baby boomers. Health Serv Res. 2002;37(4):849-884.
4. Janssen-Heijnen ML, Houterman S, Lemmens VE, et al. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol. 2005;55(3):231-240.
5. Lara PN Jr, Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001;19(6):1728-1733.
6. Unger JM, Coltman CA Jr, Crowley JJ, et al. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol. 2006;24(1):141-144.
7. Kimmick GG, Peterson BL, Kornblith AB, et al. Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001. J Clin Oncol. 2005;23(10):2201-2207.
8. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061-2067.
9. Aapro MS, Köhne CH, Cohen HJ, et al. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist. 2005;10(3):198-204.
10. Rao A, Cohen HJ. Symptom management in the elderly cancer patient: fatigue, pain, and depression. J Natl Cancer Inst Monogr. 2004;2004(32): 150-157.
11. Bernabei R, Gambassi G, Lapane K, et al; SAGE Study Group. Management of pain in elderly patients with cancer. Systematic assessment of geriatric drug use via epidemiology. [published correction appears in JAMA. 1999;281(2):136] JAMA. 1998;279(23):1877-1882.
12. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21(7):1383-1389.
13. Trimble EL, Carter CL, Cain D, et al. Representation of older patients in cancer treatment trials. Cancer. 1994;74(7 suppl):2208-2214.
14. Kemeny MM, Peterson BL, Kornblith AB, et al. Barriers to clinical trial participation by older women with breast cancer [published correction appears in J Clin Oncol. 2004;22(23):4811]. J Clin Oncol. 2003;21(12):2268-2275.
15. Yee KW, Pater JL, Pho L, et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol. 2003;21(8): 1618-1623.
16. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457-3465.
17. Zafar SF, Heilbrun LK, Vishnu P, et al. Participation and survival of geriatric patients in phase I clinical trials: the Karmanos Cancer Institute (KCI) experience. J Geriatr Oncol. 2011;2(1):18-24.
18. Palaia I, Loprete E, Musella A, et al. Chemotherapy in elderly patients with gynecological cancer. Oncology. 2013;85(3):168-172.
19. Giovanazzi-Bannon S, Rademaker A, Lai G, et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol. 1994;12(11):2447-2452.
20. LoConte NK, Smith M, Alberti D, et al. Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy. Cancer Chemother Pharmacol. 2010;65(4):775-780.
21. Javid SH, Unger JM, Gralow JR, et al. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). Oncologist. 2012;17(9):1180-1190.
22. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005;23(13):3112-3124.
23. Foster JA, Salinas GD, Mansell D, et al. How does older age influence oncologists' cancer management? Oncologist. 2010;15(6):584-592.
24. Townsley CA, Chan KK, Pond GR, et al. Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer. 2006;6:34.
25. Jenkins V, Farewell V, Farewell D, et al; TTT Steering Committee. Drivers and barriers to patient participation in RCTs. Br J Cancer. 2013;108(7): 1402-1407.
26. Umutyan A, Chiechi C, Beckett LA, et al. Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign. Cancer. 2008;112(1):212-219.
27. Garrido-Laguna IL, Janku F, Vaklavas C, et al. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer. 2012;118(5): 1422-1428.
28. van Heeckeren WJ, Fu P, Barr PM, et al. Safety and tolerability of phase I/II clinical trials among older and younger patients with acute myelogenous leukemia. J Geriatr Oncol. 2011;2(3):215-221.
29. Baggstrom MQ, Velcheti V, Malik M, et al. Barriers for accrual to clinical trials in adult patients (pts) with non-small cell lung cancer: P1-250. J Thorac Oncol. 2007;2(8):S838.
30. Hempenius L, Slaets JP, Boelens MA, et al. Inclusion of frail elderly patients in clinical trials: solutions to the problems. J Geriatr Oncol. 2013;4(1):26-31.
31. Herrera AP, Snipes SA, King DW, et al. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health. 2010;100(suppl 1):S105-S112.
32. Kornblith AB, Kemeny M, Peterson BL, et al. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer. 2002;95(5):989-996.
33. Yourman LC, Lee SJ, Schonberg MA, et al. Prognostic indices for older adults: a systematic review. JAMA. 2012;307(2):182-192.
34. Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377-3386.
35. National Institues of Health (NIH) Revitalization Act. Subtitle B: §131- 133; 1993.
36. Extermann M, Chen H, Cantor AB, et al. Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer. 2002;38(11):1466-1473.
37. Hamaker ME, Stauder R, van Munster BC. On-going clinical trials for elderly patients with a hematological malignancy: are we addressing the right end points? Ann Oncol. 2014;25(3):675-681.